Vicky Hsu
United States Food and Drug Administration(US)Center for Drug Evaluation and Research(US)
Publications by Year
Research Areas
Chronic Myeloid Leukemia Treatments, Acute Myeloid Leukemia Research, Lung Cancer Treatments and Mutations, Chronic Lymphocytic Leukemia Research, Pharmacogenetics and Drug Metabolism
Most-Cited Works
- → Application of Physiologically Based Pharmacokinetic (PBPK) Modeling to Support Dose Selection: Report of an FDA Public Workshop on PBPK(2015)267 cited
- → FDA Approval Summary: Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Carcinoma(2020)179 cited
- → Predicting the Effect of Cytochrome P450 Inhibitors on Substrate Drugs: Analysis of Physiologically Based Pharmacokinetic Modeling Submissions to the US Food and Drug Administration(2014)143 cited
- → FDA Approval Summary: Ivosidenib for Relapsed or Refractory Acute Myeloid Leukemia with an Isocitrate Dehydrogenase-1 Mutation(2019)135 cited
- → Advancing Predictions of Tissue and Intracellular Drug Concentrations Using In Vitro, Imaging and Physiologically Based Pharmacokinetic Modeling Approaches(2018)114 cited
- → Predicting the Effect of CYP3A Inducers on the Pharmacokinetics of Substrate Drugs Using Physiologically Based Pharmacokinetic (PBPK) Modeling: An Analysis of PBPK Submissions to the US FDA(2015)93 cited
- → Towards Quantitation of the Effects of Renal Impairment and Probenecid Inhibition on Kidney Uptake and Efflux Transporters, Using Physiologically Based Pharmacokinetic Modelling and Simulations(2013)86 cited
- → PBPK Modeling of the Effect of Reduced Kidney Function on the Pharmacokinetics of Drugs Excreted Renally by Organic Anion Transporters(2017)80 cited
- → The Application of Physiologically Based Pharmacokinetic Modeling to Predict the Role of Drug Transporters: Scientific and Regulatory Perspectives(2016)50 cited
- → The Prevalence of Major Depressive Disorder and Low Self-Esteem in Medical Inpatients(1996)31 cited